Sanofi could be months away from wider US approval for Tzield, its first-in-class drug for delaying the progression of type 1 ...
Immunocore is expanding its ImmTAX platform into autoimmune disease, outlining plans at the 44th Annual JP Morgan Healthcare ...
A researcher is planning on investigating potential treatments aimed at the root causes of type 1 diabetes. At the (MUSC), ...
This article is part of “Innovations In: Type 1 Diabetes,” an editorially independent special report that was produced with financial support from Vertex. On one wall of endocrinologist Kevan Herold’s ...
News-Medical.Net on MSN
Reprogramming immunity to protect beta cells in type 1 diabetes
In the battle against type 1 diabetes (T1D), one researcher at the Medical University of South Carolina (MUSC) is leading a ...
Sanofi’s Teizeild approved in the EU for patients with stage 2 type 1 diabetesApproval based on the TN-10 phase 2 study that demonstrated a ...
European Commission approves Sanofi’s Teizeild to treat patients with stage 2 type 1 diabetes: Paris Tuesday, January 13, 2026, 11:00 Hrs [IST] The European Commission has appro ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback